The newest therapeutically approach of ?diabesity? using glp-1 ra molecules: impact of the oral formulation

Co -existing diabetes and obesity, frequently described by the term "diabesity", is a major health problem associated with increased long-term complications and mortality. The management of "diabesity" could be challenging, because several anti -diabetic drugs cause weight gain. Glucagon-like peptide receptor agonists (GLP-1 RAs) have been demonstrated to be effective agents for achieving glycaemic control in addition to reducing body weight in patients with type 2 diabetes. Oral semaglutide, the first oral formulation of a GLP-1 RA, is an important therapeutic option for individuals with a preference for oral therapy. This medication was created by co-formulating the semaglutide molecule with an absorption enhancer (SNAC) to overcome the difficulties of oral peptide administration. The introduction of an oral GLP-1 RA broadens the therapeutic choices for patients and represents an important milestone in the management of "diabesity".